PARP inhibitor

Overview

Poly(ADP-ribose) polymerase (PARP) inhibitors are a class of targeted anticancer agents that exploit defects in DNA damage repair pathways, particularly homologous recombination (HR). PARP enzymes play a central role in detecting and repairing single-strand DNA breaks; when inhibited, unresolved breaks collapse replication forks into double-strand breaks. In tumor cells already harboring deficiencies in HR — such as those with loss-of-function mutations in BRCA1 or BRCA2 DNA repair associated genes — this dual impairment of repair pathways leads to synthetic lethality, resulting in selective cancer cell death while largely sparing normal cells. olaparib, one of the earliest and most clinically validated agents in this class, exemplifies the mechanism and has been approved across multiple HR-deficient tumor types including ovarian, breast, and prostate Cancers.

The therapeutic utility of PARP inhibitors is closely tied to the concept of BRCAness — a broader genomic phenotype characterized by deficient homologous recombination repair (HRD), even in the absence of germline BRCA mutations. The presence of PTEN loss and other HR pathway alterations has been associated with sensitivity to this drug class. Understanding and expanding the HRD-positive patient population, overcoming intrinsic and acquired resistance, and identifying synergistic combination strategies represent the principal frontiers of contemporary PARP inhibitor research.

Recent Publications Summary

Recent publications have continued to evaluate PARP inhibitors in settings defined by DNA repair vulnerability, treatment resistance, and combination strategies. In a randomized phase 2 study in germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, the novel glucuronide prodrug TSL-1502, a PARP inhibitor prodrug, was tested against investigator’s choice chemotherapy. Objective response rates were 36.0% with 350 mg daily, 55.6% with 500 mg daily, and 40.0% with chemotherapy, with median progression-free survival of 5.6, 8.8, and 9.2 months, respectively 42572030Aug.

Mechanistic and preclinical studies further supported PARP inhibitor sensitivity in tumors with homologous recombination defects. A newly described HPV-negative cervical cancer model with pathogenic alterations in DNA damage repair genes, including BRCA2, RAD51, and MLH1, showed sensitivity to the PARP inhibitor olaparib, and this effect was enhanced by combination with platinum-based chemotherapy; BRCA1/2-proficient cervical cancer cells were more resistant 42527451Jul. In triple-negative breast cancer, a novel SYK inhibitor was reported to suppress DNA repair signaling and show synergy with olaparib, indicating a potential combination approach to overcome homologous recombination-mediated resistance 42304805Jun.

Other studies focused on the tumor microenvironment and acquired resistance to PARP inhibition. In high-grade serous ovarian carcinoma, genomic instability was linked to STING-driven WNT signaling, POSTN+ myofibroblast-like cancer-associated fibroblasts, and immunosuppression that limited PARP inhibitor efficacy; POSTN blockade reinvigorated T-cell cytotoxicity and potentiated PARP inhibition in ovarian and breast cancer models 42202048May. In hereditary breast cancer, genomic profiling identified distinct subtypes including a homologous recombination-deficient group, reinforcing the relevance of DNA repair defects for PARP inhibitor-based precision oncology 41991965Apr.

Clinical use beyond initial PARP inhibitor exposure was also examined in platinum-sensitive recurrent ovarian cancer. One study evaluated how prior PARP inhibitor exposure affected the efficacy of platinum-based chemotherapy 41882282Mar, while another assessed PARP inhibitor rechallenge plus bevacizumab as maintenance therapy in patients previously treated with a PARP inhibitor 41609513Jan. A broader review of metastatic castration-resistant prostate cancer also highlighted PARP inhibitors as a key strategy for tumors with homologous recombination repair deficiencies 41992975Apr.

What Changes, What Holds

1. A PARP-inhibitor prodrug remains competitive with chemotherapy in BRCA-mutated metastatic breast cancer
REINFORCES TSL-1502 extends the established BRCA/HRD-sensitive use of PARP-targeted therapy rather than revising it, because it is still being tested in the same DNA-repair-vulnerable breast cancer setting the Overview already treats as valid for this class. The main implication is translational: prodrug design may alter dosing, tolerability, or delivery, but the paragraph does not establish a new biological role or overturn the synthetic-lethal model 42572030Aug.

2. DNA-repair defects continue to define olaparib sensitivity, while platinum and SYK-based combinations may broaden utility
REINFORCES The cervical-cancer and triple-negative breast-cancer findings sharpen, rather than replace, the Overview’s account that PARP inhibitors work best in homologous recombination-deficient tumors. olaparib sensitivity tracked with BRCA2/RAD51/MLH1-altered DNA-repair vulnerability, and combination strategies appeared to deepen that effect or counter resistance. Because these are mechanistic and preclinical, they mainly support expanding biomarker-guided combination research rather than changing clinical indications 42527451Jul42304805Jun.

3. tumor microenvironmental resistance limits PARP inhibitor benefit and may be therapeutically reversible
NEW DIRECTION Genomic instability, fibroblast programs, and immune suppression are presented as determinants of PARP inhibitor efficacy, which goes beyond the Overview’s focus on intrinsic homologous recombination defects as the main selector of response. That does not contradict synthetic lethality; it adds a resistance layer the baseline does not cover. The POSTN/STING/WNT axis and the hereditary breast-cancer subtype analysis point to broader precision-oncology stratification, but the microenvironmental mechanism remains preclinical and unsettled 42202048May41991965Apr.

4. Prior PARP inhibitor exposure now becomes a relevant variable in later ovarian-cancer treatment decisions
NEW DIRECTION Prior PARP inhibitor use, rechallenge, and maintenance sequencing introduce a treatment-history dimension that the Overview does not discuss. The established account says these drugs are useful in HR-deficient tumors; it does not yet address what happens after exposure or how benefit changes on retreatment. The ovarian-cancer studies therefore extend the class into questions of resistance, sequencing, and post-PARP management, while the prostate-cancer review simply reinforces the HRD-linked scope already known 41882282Mar41609513Jan.

Overview update candidates: tumor microenvironmental resistance mechanisms; prior PARP inhibitor exposure; rechallenge; and sequencing as clinically relevant variables.